Skip to content
Delayed ~15 min

REGN Regeneron Pharmaceuticals

Permanent stock page ↗

Health Care · S&P 500 · Nasdaq 100

Next earnings: Thu 28 Jan 2027 · estimated

What 33 analyst firms say about Regeneron Pharmaceuticals: their latest ratings, price targets and how far the stock is from them. How it works

904.35 USD+1.45 (+0.16%) today
Price as of 6 Nov 16:00 ET

Analyst window: Latest analyst report within last 1 year

Analyst view · last 1Y

−6.6%to the avg target 844.71 USD−59.64 USD
Buy 25 · Hold 10 · Sell 0

35 rated views · 36 analyst/firm records · 33 firms

Latest report30 Oct 2026avg report date 6 Aug
Target rangeLowest to highest analyst target, not a forecast

Radar score

  • Nasdaq 100 · Top Picks · 6MNot scored · Average target is not above the current price
  • Nasdaq 100 · Safest consensus · 6MNot scored · Average target is not above the current price
Other indices (1)
  • S&P 500 · Top Picks · 6MNot scored · Average target is not above the current price
  • S&P 500 · Safest consensus · 6MNot scored · Average target is not above the current price

Recent analyst activity · last 90 days

Our tracked history has 38 reports on REGN from 25 analyst firms in the last 90 days (33 firms in the past year).

Comparing each firm's latest target with its previous one: 15 raised their price target, 4 left it unchanged and 3 have their first observed target in the past year.

Ratings, latest available report against the previous one: 0 upgrades and 1 downgrade.

Latest observed target change: Baird raised its target from $761.00 (set 31 Jul 2026) to $875.00 on 2 Nov 2026.

Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.

FirmAnalystLatest ratingReport dateLatest target (USD)
ArgusJasper HellwegBuy1 Oct 2026850.00 USD
BairdBrian P SkorneyHold31 Jul 2026761.00 USD
Bank of America SecuritiesTim AndersonBuy7 Jan 2026860.00 USD
BarclaysEliana MerleBuy31 Jul 2026917.00 USD
BenchmarkRobert WassermanBuy7 Jul 2026185.00 USD
BernsteinJeffrey WalchHold29 Jul 2026756.00 USD
BernsteinWilliam PickeringHold14 Aug 2026756.00 USD
BMO Capital MarketsEvan David SeigermanBuy9 Sep 2026920.00 USD
Canaccord GenuityJohn NewmanBuy28 Oct 2026922.00 USD
Cantor FitzgeraldCarter GouldBuy31 Jul 2026795.00 USD
CitigroupGeoff MeachamHold30 Oct 2026825.00 USD
DBSNico ChenBuy29 May 2026910.00 USD
DZ BankElmar KrausBuy3 Feb 2026850.00 USD
Evercore ISICory KasimovBuy22 Oct 2026Conflicting reports · excluded
Goldman SachsSalveen RichterBuy20 Jul 2026968.00 USD
GuggenheimBrad CaninoBuy3 Aug 20261,030.00 USD
GuggenheimYatin SunejaBuy21 Jul 2026Conflicting reports · excluded
HSBCRajesh KumarBuy10 Sep 2026920.00 USD
JefferiesAkash TewariBuy1 Oct 2026Conflicting reports · excluded
JPMorganChris SchottBuy6 Oct 2026950.00 USD
Leerink PartnersDavid RisingerHold17 Aug 2026824.00 USD
Morgan StanleyMatthew HarrisonHold7 Oct 2026779.00 USD
OppenheimerMatthew BieglerBuy2 Feb 2026865.00 USD
Piper SandlerBiren AminBuy19 Oct 2026865.00 USD
Raymond JamesChristopher RaymondBuy19 Oct 2026—
RBC Capital MarketsBrian AbrahamsHold8 Oct 2026810.00 USD
RedburnSimon BakerBuy1 May 20261,000.00 USD
ScotiabankLouise ChenHold20 Aug 2026770.00 USD
TD CowenTyler Van BurenBuy21 Oct 2026980.00 USD
TruistGregory RenzaBuy7 Oct 2026780.00 USD
UBSJoon LeeBuy14 Oct 2026978.00 USD
UBSTrung HuynhBuy15 Oct 2026978.00 USD
Weiss RatingsUnnamed analyst—21 Sep 2026—
Wells FargoMohit BansalHold31 Jul 2026750.00 USD
Wolfe ResearchAlexandria HammondBuy19 May 2026860.00 USD
Data feed RESEARCHResearch TeamHold2 Oct 2026772.00 USD

Partial coverage · checked 6 Nov (6 Nov 2026, 04:01 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.